NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Lucid Diagnostics Inc. Common Stock (NASDAQ: LUCD)
LUCD Technical Analysis
5
As on 9th Jun 2023 LUCD STOCK Price closed @ 1.75 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.73 & Strong Sell for SHORT-TERM with Stoploss of 4.02 we also expect STOCK to react on Following IMPORTANT LEVELS. |
LUCDSTOCK Price
Open | 1.73 | Change | Price | % |
High | 1.82 | 1 Day | 0.00 | 0.00 |
Low | 1.71 | 1 Week | 0.16 | 10.06 |
Close | 1.75 | 1 Month | 0.26 | 17.45 |
Volume | 86522 | 1 Year | -3.25 | -65.00 |
52 Week High 5.37 | 52 Week Low 1.17 |
NASDAQ USA Most Active Stocks
TSLA | 244.40 | 4.06% |
TTOO | 0.07 | -12.50% |
SOFI | 8.18 | 0.74% |
FFIE | 0.33 | 6.45% |
PONO | 1.72 | 2.38% |
AMD | 124.92 | 3.20% |
IDEX | 0.06 | 0.00% |
NKLA | 0.70 | 14.75% |
AMZN | 123.43 | -0.66% |
AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
LUCD Daily Charts |
LUCD Intraday Charts |
Whats New @ Bazaartrend |
LUCD Free Analysis |
|
LUCD Important Levels Intraday
RESISTANCE | 1.96 |
RESISTANCE | 1.89 |
RESISTANCE | 1.85 |
RESISTANCE | 1.81 |
SUPPORT | 1.69 |
SUPPORT | 1.65 |
SUPPORT | 1.61 |
SUPPORT | 1.54 |
LUCD Forecast April 2024
4th UP Forecast | 5.62 |
3rd UP Forecast | 4.38 |
2nd UP Forecast | 3.61 |
1st UP Forecast | 2.85 |
1st DOWN Forecast | 0.65 |
2nd DOWN Forecast | -0.11 |
3rd DOWN Forecast | -0.88 |
4th DOWN Forecast | -2.12 |
LUCD Weekly Forecast
4th UP Forecast | 4.14 |
3rd UP Forecast | 3.37 |
2nd UP Forecast | 2.90 |
1st UP Forecast | 2.43 |
1st DOWN Forecast | 1.07 |
2nd DOWN Forecast | 0.60 |
3rd DOWN Forecast | 0.13 |
4th DOWN Forecast | -0.64 |
LUCD Forecast2024
4th UP Forecast | 10.94 |
3rd UP Forecast | 7.99 |
2nd UP Forecast | 6.17 |
1st UP Forecast | 4.35 |
1st DOWN Forecast | -0.85 |
2nd DOWN Forecast | -2.67 |
3rd DOWN Forecast | -4.49 |
4th DOWN Forecast | -7.44 |
Lucid Diagnostics Inc. Common Stock ( NASDAQ USA Symbol : LUCD )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
LUCD Other Details
Segment | EQ | |
Market Capital | 356973760.00 | |
Sector | Healthcare | |
Industry | Medical Devices | |
Offical website | > echo $website ; ?> |
LUCD Address
LUCD Latest News
LUCD Business Profile
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc. Address:
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service